Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Michelle D. Kelsey(Duke University), Neha J. Pagidipati(Alnylam Pharmaceuticals (United States)), Christopher B. Granger(Duke University), Eric D. Peterson(Duke University), Darren K. McGuire, Adam J. Nelson(Clinical Research Institute), Jennifer B. Green
Cited by 95
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
An Updated Definition of Stroke for the 21st Century
|Stroke|2013|3.5k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation
|New England Journal of Medicine|2019|1.9k